Literature DB >> 32017073

Decreased glucose bioavailability and elevated aspartate metabolism in prostate cancer cells undergoing epithelial-mesenchymal transition.

Yule Chen1,2, Ke Wang1,2, Tianjie Liu1, Jiaqi Chen1,2, Wei Lv1, Wenjie Yang1, Shan Xu1,2, Xinyang Wang1,2, Lei Li1,2.   

Abstract

Prostate cancer (PCa) is a common malignancy with a high tendency for metastasis. Epithelial-mesenchymal transition (EMT) plays a crucial role in PCa metastasis. Metabolic reprogramming offers metabolic advantages for cancer development and could result in the discovery of novel targets for cancer therapy. However, the metabolic features of PCa cells undergoing EMT remain unclear. We used metabolome and transcriptome analyses and found that PCa cells undergoing EMT showed impaired glucose utilization. In vitro studies demonstrated that PCa cells undergoing EMT were less addicted to glucose than epithelial-like PCa cells. However, cells that underwent EMT had higher levels of aspartate and its downstream metabolites, indicative of upregulated aspartate metabolism. As aspartate is a contributor for EMT and metastasis in human cancer cells, we conclude that this metabolic reprogramming may play a vital role in EMT and PCa progression.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  aspartate; epithelial-mesenchymal transition; glucose; metabolism; prostate cancer

Year:  2020        PMID: 32017073     DOI: 10.1002/jcp.29490

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Amino Acid Metabolism in Cancer Drug Resistance.

Authors:  Hee-Chan Yoo; Jung-Min Han
Journal:  Cells       Date:  2022-01-02       Impact factor: 6.600

Review 2.  Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Authors:  Nuria Gómez-Cebrián; José Luis Poveda; Antonio Pineda-Lucena; Leonor Puchades-Carrasco
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 3.  Recent Metabolomics Analysis in Tumor Metabolism Reprogramming.

Authors:  Jingjing Han; Qian Li; Yu Chen; Yonglin Yang
Journal:  Front Mol Biosci       Date:  2021-11-25

4.  Metabolic characterization and metabolism-score of tumor to predict the prognosis in prostate cancer.

Authors:  Yanlong Zhang; Xuezhi Liang; Liyun Zhang; Dongwen Wang
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

Review 5.  Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality?

Authors:  Gio Fidelito; Matthew J Watt; Renea A Taylor
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

6.  Effects of glutamate and aspartate on prostate cancer and breast cancer: a Mendelian randomization study.

Authors:  Yindan Lin; Ze Yang; Jingjia Li; Yandi Sun; Xueyun Zhang; Zihao Qu; Yan Luo; Lihong Zhang
Journal:  BMC Genomics       Date:  2022-03-16       Impact factor: 3.969

7.  Plasma Metabolites Forecast Occurrence and Prognosis for Patients With Diffuse Large B-Cell Lymphoma.

Authors:  Fei Fei; Meihong Zheng; Zhenzhen Xu; Runbin Sun; Xin Chen; Bei Cao; Juan Li
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

Review 8.  The Integration of Metabolomics with Other Omics: Insights into Understanding Prostate Cancer.

Authors:  Eleazer P Resurreccion; Ka-Wing Fong
Journal:  Metabolites       Date:  2022-05-27

Review 9.  The Epithelial-Mesenchymal Transition at the Crossroads between Metabolism and Tumor Progression.

Authors:  Monica Fedele; Riccardo Sgarra; Sabrina Battista; Laura Cerchia; Guidalberto Manfioletti
Journal:  Int J Mol Sci       Date:  2022-01-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.